Sulindac: Therapeutic Implications of the Prodrug/Pharmacophore Equilibrium
- 1 January 1981
- journal article
- review article
- Published by Informa UK Limited in Drug Metabolism Reviews
- Vol. 12 (2), 325-337
- https://doi.org/10.3109/03602538108994035
Abstract
Sulindac is a prodrug which, following absorption, rapidly attains a metabolic equilibrium with its active pharmacophore, the sulfide metabolite. At the level of the whole body, the reversible interconversion sulindac in equilibrium sulfide, and the differing distributional and excretory properties of each, provide a theoretical basis for the long plasma half-life of active drug and, in animal species, for the favorable gastrointestinal tolerance observed. In all organ cells examined, and in macrophages, enzyme systems mediating each of the opposing biotransformations between prodrug and active sulfide are present: sulindac reductase in the cytoplasm, and the sulfide oxidase activity in microsomes. Estimated metabolic rate constants for intracellular pools are of the order 0.1-0.3 min-1. It is thus proposed that sulfide, which is oxidized to sulindac in the course of scavenging oxidizing radicals generated in inflammatory responses, may be efficiently regenerated in situ.Keywords
This publication has 6 references indexed in Scilit:
- Enzymatic Reduction of Methionine Sulfoxide.In VitroExperiments with Rat Liver and KidneyBioscience, Biotechnology, and Biochemistry, 1979
- Enterohepatic Recirculation of Drugs as a Determinant of Therapeutic RatioDrug Metabolism Reviews, 1979
- Comparative disposition of sulindac and metabolites in five speciesBiochemical Pharmacology, 1978
- The disposition of sulindacClinical Pharmacology & Therapeutics, 1977
- Sulfoxide Reduction in Relation to Organophosphorus Insecticide DetoxificationScience, 1976
- Studies on the Mode of Action of Non-Steroidal Anti-Inflammatory AgentsPublished by Springer Science and Business Media LLC ,1972